Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | — | — | — | — | 1 |
Liposarcoma | D008080 | — | — | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Drug common name | SIREMADLIN |
INN | siremadlin |
Description | Siremadlin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Small molecule |
Drug class | ubiquitin ligase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1 |
PDB | — |
CAS-ID | 1448867-41-1 |
RxCUI | — |
ChEMBL ID | CHEMBL3653256 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 0282IF4JC8 (ChemIDplus, GSRS) |